Stocktwits on MSN
Bayer Stock Fuels Hyper Bullish Retail Mood After Confirming New Stroke Study Met Key Goals Following 2023 Halt
Bayer said its new Phase III stroke study of asundexian hit both primary efficacy and safety goals. ・The update comes two ...
Emirates News Agency on MSN
Bayer’s Asundexian meets main goals in Phase III stroke trial
Bayer Sunday announced positive topline results from the global Phase III study OCEANIC-STROKE, with its investigational, once daily, oral FXIa inhibitor asundexian.The study met its primary efficacy ...
Ischemic stroke, a leading cause of disability and mortality worldwide, is a complex cerebrovascular event with outcomes ...
Researchers at University Medical Center Maastricht and international partners report that a single shot of the drug ...
A low dose of colchicine — a commonly used gout drug — helped reduce the risk of heart attack and stroke in people with ...
A research paper by scientists at the Capital Medical University evaluated sex differences in stroke recurrence among ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback